Jami's Story - Lung Cancer

"I quickly learned that if you have a set of lungs, you can get lung cancer." - Jenna, whose mother Jami was diagnosed with BRAF V600E-mutant metastatic non-small cell lung cancer.

Dear Scientist: Bladder Cancer Patients Face One of the Highest Risks of Recurrence. Can Science Offer Peace of Mind?

Brian, who was diagnosed with early-stage bladder cancer, sat down with a Pfizer scientist to talk about the mental toll of lifelong surveillance and the future of immunotherapy.

Health Answers by Pfizer

Health Answers by Pfizer is a consumer digital experience powered by generative artificial intelligence that allows you to ask your biggest and smallest health and wellness questions - anytime, anywhere - and receive real-time, relevant responses and next steps.

Helping Your Loved One Stay Engaged in His Care

Explore caregiver-focused resources to help you support your loved one throughout his prostate cancer journey and help stay engaged and confident in his care.

Colorectal Cancer - Changing the Story

We are advancing breakthroughs to help patients take control of their futures. With ongoing innovation in precision medicine, we aim for brighter outcomes for patients facing colorectal cancer.

Breaking Barriers in Cancer Care Disparities

"Change the OddsTM: Uniting to Improve Cancer Outcomes" is an American Cancer Society initiative with sponsorship funding from Pfizer designed to bridge the gap in cancer care disparities. We are advancing breakthroughs to help patients take control of their futures. With ongoing innovation in precision medicine, we aim for brighter outcomes for patients facing colorectal cancer.

Brighter Together: How the Pharmaceutical Industry is Shining a Light on a Rare Cause of Heart Failure

The causes of heart failure differ widely among affected individuals. And identifying the underlying cause - especially if it's rare - can be tricky.

Items of Interest

Have a Question About Your Benefits?

Visit the Pfizer Benefits Center for answers!

Visit the
Community Corner

Connect with former colleagues, view recent retirements and more!

Connected. Active. Involved.

Welcome to the official website for retirees of Pfizer and its legacy organizations.


Pfizer News

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
December 10, 2025
Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma
December 09, 2025
HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors
December 06, 2025
Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance
December 01, 2025
U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
November 21, 2025
Pfizer Completes Acquisition of Metsera
November 13, 2025
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 12, 2025
Pfizer Responds to Delaware Chancery Court Ruling
November 05, 2025
Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement
October 31, 2025
Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
October 31, 2025
Pfizer Addresses Proposal for Metsera
October 30, 2025
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
October 19, 2025
Pfizer's BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
October 19, 2025
PADCEVTM Plus KEYTRUDATM, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
October 18, 2025
TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial
October 14, 2025
Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025
October 13, 2025
Pfizer Declares Fourth-Quarter 2025 Dividend
October 09, 2025
Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients
September 30, 2025
Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025
September 25, 2025
Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts
September 23, 2025
Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
September 22, 2025
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
September 08, 2025
Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
August 27, 2025
PADCEVTM Plus KEYTRUDATM Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
August 12, 2025
Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance
August 05, 2025
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
July 25, 2025
Pfizer Completes Licensing Agreement with 3SBio
July 24, 2025
XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
July 10, 2025

Click here to view all Pfizer News stories.

Join the Pfizer Plus Community Corner

When you join the PfizerPlus.com community, you can get access to our special “member’s only” features including:

  • Member Only Content
  • Email Updates
  • PfizerPlus.com Community